Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
about
Treatment Individualization in Colorectal CancerMolecular phenotypes of colorectal cancer and potential clinical applicationsEarly phase clinical trials to identify optimal dosing and safetyDual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerEpidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practiceMulti-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies.Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Tumour heterogeneity in the clinic.Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceClinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Molecular markers predictive of chemotherapy response in colorectal cancerNext-Generation Sequencing to Guide Clinical Trials.c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastasesMolecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.Clinical application of high-throughput genomic technologies for treatment selection in breast cancer.PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.Tumor heterogeneity in the clinic: is it a real problem?PI3K/AKT signaling pathway and cancer: an updated review.Patient-centric trials for therapeutic development in precision oncology.The changing landscape of phase I trials in oncology.Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.Early investigational tubulin inhibitors as novel cancer therapeutics.A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.Towards individualized cancer therapy: Challenges and prospects.PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience.Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.
P2860
Q26776215-9E3CA741-24FC-410A-AF27-1A2FB4E17FCAQ26785725-44605224-7EA7-415C-AD48-316E8ABE5A6AQ26865076-F4D316E2-918A-47E4-91BD-247D3D32B894Q27324821-FF50B2C3-655D-4041-A184-FE161185771AQ33556032-F252FA99-BB97-4534-8474-84BB3E4F6330Q33577844-56EAC891-ADE5-4B5C-8D24-331BB2DE7408Q33686447-D05FACDD-FF3A-44E3-B190-524B3251FFF0Q34153696-35323F3D-F7C5-45A1-A727-997370B60032Q34372080-1E71AD0A-B38D-4088-B7F7-691164BF4056Q34619163-656883F1-3FBA-4A83-8736-80E1177C06D2Q34619293-2D49A3AE-C07E-4D2D-B803-96C1C64019B4Q34781347-AE4DCC0A-AD31-41CF-91DD-A76928BF3AD7Q35051660-8399C658-449F-4E8F-B995-A7413471575BQ35190834-A237DB95-13A0-4D93-BB80-BA27633C5CACQ35535953-0E123C78-F596-45AB-ADFA-516E2E9F3C39Q35761956-5426B3E3-4B57-4355-BF82-0BAD462EEEDBQ36174832-EAEBBF29-1772-4C5C-9BF0-B0C99D9C90D0Q36352462-673ADF64-526B-4839-93BF-0C1393599991Q36843773-FFB27FE6-6818-49A2-A1AC-49070813F9ADQ36891050-44FEC82D-4431-4F4F-AA4D-E34789E7C0A7Q37130603-8BF834F8-48E9-42F9-88AA-7CC8BEA1900AQ37381179-250C110E-2A9F-4848-AA7F-236819360B2CQ37691245-F93B0739-0B79-46CA-A66C-A51E2A584EE5Q38084846-3254DA92-3159-4DA0-AF8F-3F8FA75AC107Q38192631-69D59BC5-4B22-4F98-B26E-9CBB35A2FE38Q38217651-7F8687E6-45E2-42D7-A560-A0B5D7D16AE6Q38607709-6581FD3A-6F18-4F7F-9454-6CB8DD7594B1Q38629203-BDF3907D-A9E5-4D3D-9068-E7A105CBF0EAQ38698206-649E6B5B-9049-457C-AA7E-DDF00CFD48DAQ38699764-55DE4A61-5143-4562-A739-346757D5DEFAQ38724110-62DB531E-EAC5-4EA1-82A2-3120ABD395AFQ38836161-D7304499-61AE-48ED-BD0D-043A126D40EBQ47130538-2CD29053-5494-4D7A-A716-8ED6B5F826E7Q47155260-39262BF7-19F3-4D0C-B74E-010BF8FAA17BQ54393310-A616F4B8-476E-4582-AF26-6171B766088CQ54958714-1B317B36-700A-4981-BE6D-351A3AF900DEQ55458851-AA00BF96-2DCC-4379-BAAC-33C918D7DD9A
P2860
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Molecular profiling of patient ...... py in phase I clinical trials.
@en
Molecular profiling of patient ...... py in phase I clinical trials.
@nl
type
label
Molecular profiling of patient ...... py in phase I clinical trials.
@en
Molecular profiling of patient ...... py in phase I clinical trials.
@nl
prefLabel
Molecular profiling of patient ...... py in phase I clinical trials.
@en
Molecular profiling of patient ...... py in phase I clinical trials.
@nl
P2093
P50
P921
P1476
Molecular profiling of patient ...... apy in phase I clinical trials
@en
P2093
Claudia Aura
Danila Serpico
Elena Elez
Gessamí Sánchez-Ollé
Jaume Capdevila
Jordi Rodon
Jose Perez-Garcia
Ludmila Prudkin
Maria Alsina
Rodrigo Dienstmann
P304
P356
10.1158/1535-7163.MCT-12-0290
P577
2012-06-21T00:00:00Z